89bio to Announce Topline Results from Phase 1b/2a Study of BIO89-100 in NASH

Rhea-AI Summary

89bio, Inc. (Nasdaq: ETNB) announced plans to share topline safety, tolerability, and efficacy data from its Phase 1b/2a study of BIO89-100 for NASH on September 14, 2020. The presentation will take place during a pre-market conference call at 8:30 AM PT, featuring a live webcast accessible through the company’s website. BIO89-100 is a glycoPEGylated analog of FGF21 aimed at treating NASH and severe hypertriglyceridemia. Investors can find further information on the event and future developments on the company’s investor relations page.

Positive

• Upcoming presentation of topline data from Phase 1b/2a study indicates progress in clinical trials.
• BIO89-100 has potential applications for treating both NASH and severe hypertriglyceridemia, broadening market opportunities.

Negative

• None.

SAN FRANCISCO, Sept. 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study of BIO89-100 in NASH in a pre-market press release and webcast to be held on Monday, September 14, 2020.

Conference Call/Webcast Details
The company will host a conference call and webcast with slides at 8:30am PT (5:30am PT) tomorrow morning, September 14. Details for the live conference call are as follows: Domestic – (833) 570-1145; International – (914) 987-7092; and Passcode - 5064866. To access the live webcast and slides, please visit “Events and Presentations” under the “Investors” section of 89bio’s website at https://ir.89bio.com/events-and-presentations. Following the live audio webcast, a replay will be available on the company’s website for 90 days.

About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of NASH and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Lori Rosen
LDR Communications
917-553-6808
lori@ldrcommunications.com

FAQ

What data will 89bio share regarding BIO89-100 on September 14, 2020?

89bio will share topline safety, tolerability, and efficacy data from its Phase 1b/2a study of BIO89-100.

What is the significance of the Phase 1b/2a study for 89bio?

The Phase 1b/2a study is crucial for determining the safety and efficacy of BIO89-100 in treating NASH.

How can investors access the conference call on September 14, 2020?

Investors can access the live conference call at 8:30 AM PT by calling either (833) 570-1145 for domestic or (914) 987-7092 for international participants.

Where can I find the replay of the BIO89-100 webcast?

The replay of the BIO89-100 webcast will be available on 89bio's website for 90 days following the live event.